High serum levels of complements C3 and C4 as novel markers for myeloma bone disease

被引:0
作者
Fengjuan Jiang
Hui Liu
Zhaoyun Liu
Jia Song
Lijuan Li
Kai Ding
Yue Ren
Fengping Peng
Zonghong Shao
Rong Fu
机构
[1] Tianjin Medical University General Hospital,Department of Hematology
来源
Annals of Hematology | 2017年 / 96卷
关键词
Multiple Myeloma; Bone Disease; Osteoclast Formation; Osteolytic Lesion; Osteoclast Precursor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:331 / 333
页数:2
相关论文
共 25 条
[1]  
Rajkumar SV(2007)Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation Best Pract Res Clin Haematol 20 665-680
[2]  
Buadi F(2013)Does complement play a role in bone development and regeneration? Immunobiology 218 1-9
[3]  
Schoengraf P(2003)Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma Int J Cancer 106 455-457
[4]  
Lambris JD(2016)Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease Ann Hematol 95 1099-1106
[5]  
Recknagel S(1993)The biological roles of the third component of complement in osteoclast formation Endocrinology 133 397-404
[6]  
Terpos E(2010)Efficient osteoclast differentiation requires local complement activation Blood 116 4456-4463
[7]  
de la Fuente J(2013)The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma Plos One 8 e58504-undefined
[8]  
Szydlo R(2014)Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease BMC Genomics 15 904-undefined
[9]  
Fu R(undefined)undefined undefined undefined undefined-undefined
[10]  
Peng F(undefined)undefined undefined undefined undefined-undefined